About this Series

Checkpoint inhibitors have shown unprecedented clinical activity across a range of cancers and have moved the field of immuno-oncology to the forefront of cancer treatment.

Clinicians and researchers qualify these success stories, however, by saying that immunotherapies are active in only a small proportion of patients, and that those patients who initially respond to therapy too frequently see their disease progress.

To find a way to checkmate cancer, investigators are examining the mechanisms of resistance and identifying strategies to expand the effectiveness of immunotherapy.

Renowned immuno-oncologists at Georgetown-Lombardi Comprehensive Cancer Center survey the tumor microenvironment and report on strategies to improve anti-tumor response of checkpoint inhibitors, with the intention of taking oncology a step closer to a cure.

Show More

Who's Who
More on a Wide Range of Tumors